Research News

OCRF Talk with Lin Zhang, M.D.

In an interview, 3-time grantee Dr. Zhang discusses his research and what it means to receive an award from OCRF…

Read on

Report from ASCO 2013–What's New in Ovarian Cancer Research

We recently returned from the annual meeting of the American Society of Clinical Oncology (ASCO), an annual event that gathers thousands of cancer researchers from around the world…

Read on

Supreme Court Strikes Down BRCA Gene Patents

In a unanimous ruling issued June 13, 2013, the US Supreme Court ruled that private companies do not have the right to patent human genes. In Association for Molecular Pathology et al. v…

Read on

June 2013 SNMMI Meeting

Society for Nuclear Medicine and Molecular Imaging (SNMMI) Advocate Report from Laurel Pracht As a member of the SNMMI Advocate Advisory Board, formed in 2010 to better bridge the gap between the patient and nuclear medicine communities, I represent…

Read on

Press Release: Ovarian Cancer Advocates Praise Supreme Court Decision on Gene Patents

Ruling Will Give Women More Options to Learn About Genetic Risk Washington, DC—The Supreme Court ruled today that a company cannot patent naturally occurring genes, including isolated gene segments, overturning a decision made by the United States…

Read on

New Meta-Analysis of Oral Contraception and Risk of Ovarian Cancer

A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use…

Read on

ASCO News: Weekly Chemo Improves Quality of Life

In research presented at the American Society of Clinical Oncology meeting this week, researchers found that shortening the break between chemotherapy sessions improved quality of life for patients, without negatively impacting efficacy…

Read on

ASCO News: Kidney Cancer Drug Delays Ovarian Cancer Relapse

Research presented at the American Society of Clinical Oncology annual meeting this week suggests that adding the drug pazopanib (trade name Votrient) to standard treatment extends progression-free survival in ovarian cancer patients by 5.6 months…

Read on

Ovarian Cancer Incidence Fell Along with Hormone Therapy Use

In a study published online in the Journal of Clinical Oncology on May 6, 2013, researchers reported results of a study investigating menopausal hormonal therapy (MHT) use and the incidence of ovarian cancer…

Read on

NCCN Releases Updated Guidelines for Ovarian Cancer Patients

The National Comprehensive Care Network has released updated guidelines for patients with ovarian cancer…

Read on

Decreases in Ovarian Cancer Correlate to Decrease in Use of Hormone Replacement Therapy

A new study shows that rates of ovarian cancer decreased around the same time that the use of hormone replacement therapy dropped off…

Read on

Update on Treatment for Recurrent Ovarian Cancer

A new article summarizes treatment options for women with recurrent ovarian cancer. The article includes information about when to treat a recurrence, what agents are available and the goals of therapy…

Read on